Certolizumab pegol

Modify Date: 2024-01-07 18:46:11

Certolizumab pegol Structure
Certolizumab pegol structure
Common Name Certolizumab pegol
CAS Number 428863-50-7 Molecular Weight N/A
Density N/A Boiling Point N/A
Molecular Formula N/A Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Certolizumab pegol


Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research[1][2].

 Names

Name Certolizumab pegol

 Certolizumab pegol Biological Activity

Description Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research[1][2].
Related Catalog
Target

TNF-α

In Vitro Certolizumab pegol (Certolizumab) neutralizes soluble TNFα with an IC90 of 3 ng/mL[2]. Certolizumab pegol (0-100 μg/mL, 1 h) completely inhibits subsequent production of IL-1β in response to LPS at concentrations over 1μg/mL in human monocytes[2]. Certolizumab pegol does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC)[2]. Certolizumab pegol does not induce apoptosis of activated human monocytes or peripheral blood lymphocytes (PBLs) or result in degranulation or loss of cell membrane integrity in polymorphonuclear cells[2].
In Vivo Certolizumab pegol (Certolizumab) (10 μg; i.p.; single dose) reduces the severity of acute pancreatitis[3]. Animal Model: Healthy Wistar Albino male rats weighing 180 to 200 g, acute edematous pancreatitis was induced via intraperitoneal injection of 80 μg/kg Cerulein (HY-A0190) (20 μg/kg, 4 times at 1-hour intervals)[3] Dosage: 10 μg Administration: Intraperitoneal administration, single dose Result: Significantly decreased the serum levels of amylase, lipase, and lactate dehydrogenase. Histopathological edema, hemorrhage, parenchymal necrosis, and infiltration scores were also decreased, along with a decrease in malondialdehyde, myeloperoxidase, TNF-α, and caspase-3 activities.
References

[1]. Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013 Jan;73(1):75-97.

[2]. Nesbitt A, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007 Nov;13(11):1323-32.

[3]. Kosekli MA, et al. Effects of Certolizumab on Cerulein-Induced Acute Pancreatitis in Rats. Pancreas. 2016 Sep;45(8):1120-5.

 Chemical & Physical Properties

No Any Chemical & Physical Properties